医薬品リファレンス
Dostarlimab
Dostarlimab is a medicine in the class oncology. It is used for cancer.
- 薬効分類: Oncology
- 効能・効果: cancer
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FF07
- 一般的な剤形
- 注射剤
- 一般的な規格
- 50 mg/ml
- 既知の相互作用
- 3 (中等度: 2 · 軽度: 1)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Dostarlimab-gxly is a humanized IgG4 monoclonal antibody that binds the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
成人の通常用量（添付文書の要約）
Primary advanced or recurrent endometrial cancer: 500 mg IV every 3 weeks for 6 cycles with carboplatin and paclitaxel, then 1,000 mg monotherapy every 6 weeks thereafter; until disease progression, unacceptable toxicity, or up to 3 years
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose.
- 授乳
- Unsafe No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.
報告されている副作用
- Fatigue/asthenia
- Anemia
- Diarrhea
- Nausea
- Peripheral neuropathy (with carboplatin/paclitaxel)
- Alopecia (with carboplatin/paclitaxel)
注意が必要な方
- Severe and fatal immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, transplant rejection) can occur in any organ; monitor liver enzymes, creatinine and thyroid function at baseline and periodically.
- Infusion-related reactions: interrupt, slow the infusion, or permanently discontinue based on severity.
- Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after PD-1/PD-L1 blocking antibody.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (3)
- Dostarlimab + Piperacillin Moderate
- Dostarlimab + Piperacillin-tazobactam Moderate
- Dostarlimab + Penicillin g Minor
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Dostarlimabの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
WebでPro+を7日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Dostarlimab used for?
Dostarlimab is a medicine in the class oncology. It is used for Cancer, Endometrial carcinoma.
What side effects have been reported with Dostarlimab?
Fatigue/asthenia, Anemia, Diarrhea, Nausea, Peripheral neuropathy (with carboplatin/paclitaxel), Alopecia (with carboplatin/paclitaxel).
Can Dostarlimab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose. Breastfeeding: Unsafe. No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.
What does Dostarlimab interact with?
MediHelp lists 3 known interactions for Dostarlimab. Moderate: 2 · Minor: 1. The most serious include Piperacillin, Piperacillin-tazobactam, Penicillin g.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
